Rapid Micro Biosystems plans $8.9 million net share and warrant offering
Rapid Micro Biosystems entered into an underwritten offering of about 5 million shares of Class A common stock, including pre-funded warrants, with accompanying Series A and Series B warrants, plus a concurrent sale to directors and officers. The company estimates net proceeds of about $8.9 million for working capital and general corporate purposes. The new shares and warrants add to the number of shares outstanding, which dilutes existing shareholders, while the cash raised supports the company's working capital.
Key points
- 3,581,000 Class A common shares plus pre-funded warrants for up to 1,463,000 shares, sold with warrants at a combined price of $1.955 per share
- Series A warrants exercisable at $1.955 and Series B warrants exercisable at $2.340, both exercisable six months after issuance
- Estimated net proceeds of about $8.9 million; the offering is expected to close on May 20, 2026
- Concurrent sale of 71,607 shares to directors and officers for gross proceeds of about $140,000
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.